Glossary_NN
of_PIN
terms_NN
Terms_NN
used_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
Report_NN
US_FPP1
equivalent_JJ
or_CC
brief_JJ
description_NOMZ
Accelerated_VBN
capital_NN
allowances_NN
Tax_NN
allowance_NN
in_PIN
excess_NN
of_PIN
depreciation_NOMZ
arising_VBG [WZPRES]
from_PIN
the_DT
purchase_NN
of_PIN
xed_JJ
assets_NN
that_TSUB
delay_VPRT
the_DT
charging_VBG
and_CC
payment_NOMZ
of_PIN
tax_NN
._.
The_DT
US_FPP1
equivalent_NN
of_PIN
tax_NN
depreciation_NOMZ
._.
Advance_NN
Corporation_NOMZ
Tax_NN
ACT_NN
An_DT
advance_NN
payment_NOMZ
of_PIN
UK_NN
tax_NN
that_TSUB
was_VBD [PASS]
made_VBN
when_RB
dividends_NN
are_VPRT [PASS]
paid_VBN
._.
American_JJ
Depositary_NN
Receipt_NN
ADR_NN
Receipt_NN
evidencing_VBG [WZPRES]
title_NN
to_PIN
an_DT
ADS_NN
._.
Each_QUAN
GlaxoSmithKline_NN
ADR_NN
represents_VPRT
two_CD
ordinary_JJ
shares_NN
._.
American_JJ
Depositary_NN
Shares_NN
ADSs_NN
Ordinary_NN
Shares_NN
registered_VBD
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
._.
Basic_JJ
earnings_GER
per_PIN
share_NN
Basic_JJ
income_NN
per_PIN
share_NN
._.
Called-up_JJ
share_NN
capital_NN
Ordinary_NN
Shares_NN
,_,
issued_VBN
and_CC
fully_AMP
paid_VBN
._.
CER_NN
growth_NN
Growth_NN
at_PIN
constant_JJ
exchange_NN
rates_NN
._.
Combined_NN
Code_NN
Guidelines_NN
required_VBN [SUAV] [WZPAST]
by_PIN
the_DT
Listing_GER
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
Authority_NOMZ
to_TO
address_VB
the_DT
principal_JJ
aspects_NN
of_PIN
Corporate_JJ
Governance_NN
._.
Currency_NN
swap_NN
An_DT
exchange_NN
of_PIN
two_CD
currencies_NN
,_,
coupled_VBN [PASTP]
with_PIN
a_DT
subsequent_JJ
re-exchange_NN
of_PIN
those_DEMO
currencies_NN
,_,
at_PIN
agreed_VBN [SUAV] [PUBV]
exchange_NN
rates_NN
and_PHC
dates_NN
._.
Dened_VBN
benefit_NN
plan_NN
Pension_NN
plan_NN
with_PIN
specic_JJ
employee_NN
benets_NN
,_,
often_RB
called_VBN
final_JJ
salary_NN
scheme_NN
._.
Dened_VBN
contribution_NOMZ
plan_NN
Pension_NN
plan_NN
with_PIN
specic_JJ
contributions_NOMZ
and_CC
a_DT
level_NN
of_PIN
pension_NN
dependent_JJ
upon_PIN
the_DT
growth_NN
of_PIN
the_DT
pension_NN
fund_NN
._.
Derivative_JJ
financial_JJ
instrument_NOMZ
A_DT
financial_JJ
instrument_NOMZ
that_TSUB
derives_VPRT
its_PIT
value_NN
from_PIN
the_DT
price_NN
or_CC
rate_NN
of_PIN
some_QUAN
underlying_VBG
item_NN
._.
Diluted_JJ
earnings_GER
per_PIN
share_NN
Diluted_JJ
income_NN
per_PIN
share_NN
._.
Employee_NN
Share_NN
Ownership_NN
Plan_NN
Trusts_VPRT
Trusts_NN
established_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Group_NN
to_TO
satisfy_VB
share_NN
based_VBN
employee_NN
incentive_NN
plans_NN
._.
Freehold_NN
Ownership_NN
with_PIN
absolute_JJ
rights_NN
in_PIN
perpetuity_NOMZ
._.
Gearing_VBG
ratio_NN
Net_JJ
debt_NN
as_IN
a_DT
percentage_NN
of_PIN
total_JJ
equity_NOMZ
._.
The_DT
Group_NN
GlaxoSmithKline_NN
plc_NN
and_CC
its_PIT
subsidiary_NN
undertakings_GER
._.
Hedging_VBG [PRESP]
The_DT
reduction_NOMZ
of_PIN
risk_NN
,_,
normally_RB
in_PIN
relation_NOMZ
to_PIN
foreign_JJ
currency_NN
or_CC
interest_NN
rate_NN
movements_NOMZ
,_,
by_PIN
making_VBG
off-setting_JJ
commitments_NOMZ
._.
Intangible_JJ
xed_JJ
assets_NN
Assets_NN
without_PIN
physical_JJ
substance_NN
,_,
such_JJ
as_IN
brands_NN
,_,
licences_NN
,_,
patents_NN
,_,
know-how_NN
and_PHC
marketing_GER
rights_NN
purchased_VBN [WZPAST]
from_PIN
outside_PLACE
parties_NN
._.
Non-equity_JJ
minority_NOMZ
interest_NN
Preference_NN
shares_NN
issued_VBN [WZPAST]
by_PIN
a_DT
subsidiary_NN
to_PIN
outside_PLACE
parties_NN
._.
Preference_NN
shares_NN
Shares_NN
issued_VBD
at_PIN
varying_VBG
dividend_NN
rates_NN
that_TSUB
are_VPRT [PASS]
treated_VBN
as_IN
outside_PLACE
interests_NN
._.
profit_NN
attributable_JJ
to_PIN
shareholders_NN
Net_JJ
income_NN
._.
Share_NN
capital_NN
Ordinary_NN
Shares_NN
,_,
capital_NN
stock_NN
or_CC
common_JJ
stock_NN
issued_VBN
and_CC
fully_AMP
paid_VBN
._.
Share_NN
premium_NN
account_NN
Additional_JJ
paid-up_JJ
capital_NN
or_CC
paid-in_PIN
surplus_NN
not_XX0
distributable_JJ
._.
Shares_NN
in_PIN
issue_NN
Shares_NN
outstanding_JJ
._.
Statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
Statement_NOMZ
of_PIN
comprehensive_JJ
income_NN
._.
Subsidiary_JJ
undertaking_GER
An_DT
afliate_NN
in_PIN
which_WDT [PIRE]
GlaxoSmithKline_NN
holds_VPRT [PRIV]
a_DT
majority_NOMZ
shareholding_GER
and_CC
or_CC
exercises_VPRT
control_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
187_CD
INVESTOR_NN
INFORMATION_NOMZ
